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Abstract
Introduction: Ionizing radiation (IR) is a widely used approach to cancer therapy, ranking second only to surgery
in rate of utilization. Responses of cancer patients to radiotherapy depend in part on the intrinsic radiosensitivity of
the tumor cells. Thus, promoting tumor cell sensitivity to IR could significantly enhance the treatment outcome
and quality of life for patients.
Methods: Mammary tumor cells were treated by a 16-base phosphodiester-linked oligonucleotide homologous to
the telomere G-rich sequence TTAGGG (T-oligo: GGTTAGGTGTAGGTTT) or a control-oligo (the partial complement,
TAACCCTAACCCTAAC) followed by IR. The inhibition of tumor cell growth in vitro was assessed by cell counting
and clonogenic cell survival assay. The tumorigenesis of tumor cells after various treatments was measured by
tumor growth in mice. The mechanism underlying the radiosensitization by T-oligo was explored by
immunofluorescent determination of phosphorylated histone H2AX (gH2AX) foci, b-galactosidase staining, comet
and Terminal deoxynucleotidyl transferase dUTP Nick End Labeling (TUNEL) assays. The efficacy of the combined
treatment was assessed in a spontaneous murine mammary tumor model.
Results: Pretreatment of tumor cells with T-oligo for 24 hours in vitro enhanced both senescence and apoptosis of
irradiated tumor cells and reduced clonogenic potential. Radiosensitization by T-oligo was associated with
increased formation and/or delayed resolution of gH2AX DNA damage foci and fragmented DNA. T-oligo also
caused radiosensitization in two in vivo mammary tumor models. Indeed, combined T-oligo and IR-treatment in
vivo led to a substantial reduction in tumor growth. Of further significance, treatment with T-oligo and IR led to
synergistic inhibition of the growth of spontaneous mammary carcinomas. Despite these profound antitumor
properties, T-oligo and IR caused no detectable side effects under our experimental conditions.
Conclusions: Pretreatment with T-oligo sensitizes mammary tumor cells to radiation in both in vitro and in vivo
settings with minimal or no normal tissue side effects.
Introduction
Breast cancer is the most common malignancy among
women in the United States. It is estimated that each
year 192,370 new cases will occur and 40,170 women
will die from the disease (American Cancer Society
Facts and Figures, 2009). Current therapies, usually in
combination with surgical excision, have reduced the
mortality from this disease but remain inadequate for
many and may produce serious side effects. Ionizing
radiation (IR) is one of the most widely used therapies
but the therapeutic effect is dependent on the sensitivity
of the breast cancer cells to radiation. Thus, promoting
tumor cell sensitivity to IR could significantly enhance
the treatment outcome and quality of life for patients.
Recent studies show that telomeres are implicated in the
maintenance of genomic stability and repairing of
damaged DNA. Therefore, telomere-based therapy may
* Correspondence: jgong@bu.edu
† Contributed equally
1Department of Medicine, Boston University School of Medicine, 72 E
Concord St, Boston, MA 02118, USA
Full list of author information is available at the end of the article
Weng et al. Breast Cancer Research 2010, 12:R71
http://breast-cancer-research.com/content/12/5/R71
© 2010 Weng et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.provide a promising approach to enhancing the effect of
radiotherapy and/or reducing its side effects.
Telomeres consist of guanine-rich tandem repeats that
prevent chromosome ends from being recognized as
DNA double-strand breaks. McClintock’sh i s t o r i c a l
observation that loss of telomeric sequences in maize
chromosomes renders DNA ends recombinogenic high-
lighted the importance of telomeres and their associated
complexes in chromosomal integrity [1]. More recent
work has established that disruption of the T-loop by
experimental DNA damage, telomere shortening or
expression of a dominant-negative mutant of loop-bind-
ing factor leads to cellular apoptosis or senescence [2,3].
A novel approach to treating cancer involves harnes-
sing innate telomere-based DNA damage responses
through use of telomere homolog oligonucleotides,
termed T-oligos. Like experimental disruption of the
normal telomere loop structure [4], T-oligo treatment of
cancer cells in vitro or in vivo leads to apoptosis and/or
senescence, depending on cell type [5-9]. However,
unlike treatments that disrupt the telomere loop, T-oli-
gos do not cause digestion of the 3’ telomere overhang
(repeats of TTAGGG sequences) or otherwise alter
endogenous chromosomes [10]. Systemic administration
of T-oligos greatly reduces tumor burden in xenograft
mouse models of human melanoma and breast carci-
noma [6,8]. In addition, when used in combination with
conventional chemotherapy to treat human lymphoma
cells in vitro or to treat a murine B cell lymphoma in a
mouse model, T-oligos reduced the dose of these toxic
agents required to achieve cell killing [11]. The detailed
mechanism of tumor inhibition by T-oligo is not fully
elucidated. However, it is believed that the guanine (G)-
rich T-oligos enhance G quadruplex formation in sin-
gle-stranded telomeric DNA (repeats of TTAGGG), stall
DNA replication forks and promote DNA damage
responses that lead to cellular senescence and apoptosis
[12]. Selective killing of malignant cells, with sparing of
normal cells, likely results from the well-recognized
greater sensitivity of malignant cells to replication stress,
especially those with abnormalities in the breast cancer-
associated gene (BRCA) pathway [13,14], with fatal col-
lapse of stalled replication forks at sites of G-quadruplex
formation.
In the present study, we tested the hypothesis that T-
oligo treatment sensitizes tumor cells to ionizing radia-
tion. T-oligos have been shown to inhibit growth and
induce apoptosis, autophagy and/or senescence in
human pancreatic, ovarian, breast cancer, melanoma,
fibrosarcoma, and glioblastoma [5-9]. Our data indicate
that pretreatment of mammary tumor cells with T-oligo
but not a control oligo sensitizes the tumor cells to
radiation in vitro and in an in vivo tumor model.
Materials and methods
Mice
Female C57BL/6 mice, six to eight weeks old, were pur-
chased from Taconic Farms (Germantown, NY, USA).
MMT mice were generated by breeding MUC1 trans-
genic (MUC1.Tg) mice with polyomavirus middle T
oncogene (PyMT)-expressing MT mice that develop
spontaneous mammary carcinomas [15,16]. Animals
were maintained in microisolator cages under specific
pathogen-free conditions. The study of mice was
approved by the Institutional Animal Care and Use
Committee of Boston University Medical Center.
Oligonucleotides
A 16-base phosphodiester-linked oligonucleotide (T-
oligo: GGTTAGGTGTAGGTTT) with 56% homology
to the human telomere G-rich sequence [7], and a con-
trol-oligo (the partial complement, TAACCCTAACCC-
TAAC) were synthesized by the Midland Certified
Reagent Company (Midland, TX, USA) and resuspended
in H20 to give a 2 mM stock solution. For the in vitro
studies, the stock solution was diluted into culture med-
ium, and added to cells at a final concentration of 40
μM. In all experiments, cells were given medium con-
taining oligonucleotide once and not refed. For the in
vivo studies, 2 mM of T-oligo and control-oligo were
diluted in sterile PBS to make a 1.2 mM concentration
and 50 μL of this solution was injected into each mouse.
Earlier studies of T-oligos employed 100% homologs
[5-11], establishing the efficacy for telomere homologs
in comparison to inactive complementary and unrelated
control sequences. However, further work revealed that
G-rich oligos with substantial but less than 100%
homology to telomeres were also effective in activation
of the DNA damage signaling pathway leading to apop-
tosis of malignant cells and that some were even more
effective than the same length 100% homologs [7]. One
of these 16-base T-oligos was selected for the present
studies.
Cell yield and counting
Primary mammary tumor cells from MMT mice were
harvested and cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM) with 10% heat-inactivated fetal calf
serum (FCS), 2 mM L-glutamine, 100 U/ml penicillin
and 100 μg/ml streptomycin. A triplicate set of cultured
cells was pre-treated with T-oligo or control-oligo at a
final concentration of 0, 10, 20, 30 or 40 μMi nD M E M
for 24 hours, and then irradiated with 0, 3, 6, 9, or 12Gy
(Cesium
137 source at a dose rate of 1.06 Gy/min). The
cells were trypsinized and collected at 0, 24, 48, 72 and
96 hours after irradiation for cell count using a cell
counter (Coulter Corp., Miami, FL, USA).
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Mammary tumor cells were trypsinized to a single-cell
suspension and seeded into 10 cm tissue culture dishes
(1 × 10
5 cells/dish). After the cells were treated with 40
μM T-oligo or control-oligo for 24 hours, they were
irradiated at different dose levels (0 to 8 Gy) and placed
thereafter in an incubator until cells in the control
groups formed multiple large clones. The colonies were
stained with 0.5% crystal violet and counted. The plating
efficiency (PE) and the surviving fraction (SF) were cal-
culated by using the formula PE = (number of colonies
formed/number of cells seeded) × 100% and SF = (num-
ber of colonies formed after treatment/number of cells
seeded × PE) × 100%. The standard radiation survival
curve was constructed and the mean lethal dose (D0),
which represents the dose required to reduce the frac-
tion of surviving cells to 37% (1/e) of its previous value,
was calculated by fitting the data with the multitarget-
single hit model and linear-quadratic model [17].
Immunofluorescent gH2AX staining
Tumor cells plated into eight-well chambers were pre-
treated with T-oligo or control-oligo for 24 hours and
then irradiated. After radiation, cells were fixed in 4%
paraformaldehyde, and then treated with a 0.2% NP40/
PBS solution for 15 minutes at room temperature. Cells
were washed with PBS and incubated for two hours
with anti-gH2AX (1:300 dilution, Upstate Biotechnology,
Lake Placid, NY, USA), followed by incubation with
FITC-conjugated anti-mouse IgG (1:100 dilution) for
one hour. Slides were immersed in 0.05 mg/ml DAPI
for five minutes and then mounted with cover slips
using ProLong® Antifade Kit (Molecular Probes Inc.,
Eugene, OR, USA). Slides were viewed with a Nikon
Eclipse E400 fluorescence microscope (Nikon Inc.,
Tokyo, Japan) and the images were captured by a digital
camera and analyzed using SPOT advanced software
(Version 4.6, Diagnostic Instrument Inc., Sterling
Heights, MI, USA). The number of gH2AX-foci per cell
was counted and determined in at least 70 cells for each
group [18].
Single cell gel electrophoresis assay
To compare the degree of DNA fragmentation, mam-
mary tumor cells were pretreated with 40 μM T-oligo
or control-oligo for 24 hours, and then subjected to irra-
diation. Three hours after radiation, cells were trypsi-
nized to single-cell suspension and adjusted to the
concentration of 1 × 10
5 cells/ml. Cell suspensions (10
μl) and 1% low melting-point (LMP) agarose (100 μl)
were gently mixed at 37°C and added onto each Comet-
Slide™ (Trevigen Inc., Gaithersburg, MD, USA). The
slides were gelled at 4°C in the dark for 30 minutes, and
then immersed in prechilled lysis solution (2.5 M NaCl,
100 mM EDTA, 10 mM Tris) for 60 minutes. Then the
slides were immersed in freshly prepared alkaline buffer
(300 mM NaOH, 1 mM EDTA, pH > 13.0) for 60 min-
utes to allow the DNA to unwind prior to electrophor-
esis at 1 Volt/cm for 30 minutes at 4°C. Air-dried slides
were stained for five minutes with 10 μl DAPI (0.05 mg/
ml), and then rinsed in cold water and covered with a
cover slip. The nuclei were analyzed by use of a fluores-
cence microscope. Hydroxyl radical-induced DNA
damage by H2O2 was used as a positive control. TriTek
CometScore™ (Version 1.5.2.6, Sumerduck, VA, USA)
software was used to measure the percentage of DNA in
tail. At least 45 cells on each slide were measured.
b-galactosidase staining
Mammary tumor cells were cultured in either medium
alone or medium containing T-oligo or control T-oligo
at a concentration of 40 μM for 24 hours, and then irra-
diated with 3 Gy. Twenty-four hours after radiation, the
cells were washed in PBS and fixed with formaldehyde/
gluteradlehyde solution (5.6% formaldehyde, 0.4% gluter-
aldehyde in PBS) for 10 minutes at room temperature
and stained with an X-gal mixture (40 mM Citrate/
Na2HPO4,5m MK 4Fe(CN)6,5m MK 3Fe(CN)6, 150
mM NaCl, 2 mM MgCl2, 1 mg/ml X-Gal) [19] for 24
hours at 37°C. To quantify the b-gal positive cells, three
to five high-power fields per mouse were selected and
b-gal positive cells were counted as described [19,20] by
two investigators.
TUNEL assay
To determine apoptosis in tumor cells treated with T-
oligo and radiation, TUNEL staining was performed
using ApopTag Plus peroxidase kit (Chemicon, Teme-
cula, CA, USA) in a method previously described with
some modification [21,22]. To quantify the apoptotic
cells, three to five high-power fields per mouse were
selected and apoptotic cells were counted by two
investigators.
Tumorigenesis of cancer cells treated with T-oligo and
radiation
To assess the growth potential of T-oligo and IR-treated
tumor cells in mice, mammary tumor cells were supple-
mented in culture with T-oligo for 24 hours, and then
irradiated with 3 Gy. The tumor cells cultured in med-
ium alone or containing control-oligo were used as con-
trol groups. After radiation, the cells were washed and
prepared for injection. Untreated cells were resuspended
in PBS, while the control-oligo and T-oligo-treated cells
were resuspended in 1.2 mM control-oligo or T-oligo in
PBS. T-oligo or control-oligo-treated and medium only
(diluent)-treated tumor cells (1 × 10
6 cells in 0.1 ml
volume/mouse) were injected respectively in the right or
Weng et al. Breast Cancer Research 2010, 12:R71
http://breast-cancer-research.com/content/12/5/R71
Page 3 of 11left flanks of syngeneic wild-type mice. Untreated tumor
cells with or without IR were also injected as controls.
The mice were followed for up to 30 days after the
tumor inoculation and tumor growth was measured
with calipers every two days. The tumor incidence was
also recorded.
In vivo treatment
MMT mice at approximately 73 days of age were
injected intraductally in the right chest mammary gland
with 50 μL of a T-oligo solution (210 μg=6 0n m o li n
50 μL of PBS). The left chest mammary gland in the
same mouse was injected with the same dosage of con-
trol-oligo. After seven to eight daily injections, the mice
were sedated with intraperitoneal administration of keta-
mine (75 mg/kg) and xylazine (5 mg/kg) and placed in a
special Irradiation Pie cage. The mammary glands (chest
area) were irradiated with 3 Gy IR with the rest of the
body covered by lead foil. The mice were sacrificed 10
days after the radiation. The treated mammary glands
were then removed, whole-mounted, formalin-fixed,
stained in carmine alum, and photographed with a digi-
tal camera. To quantify the tumor burden, digital images
of all whole mounted mammary glands were analyzed
using SPOT advanced software.
Statistical analysis
Statistical significance was determined using Student’s t-
tests or X
2-test. One way-ANOVA was used for analysis
of data with more than two subgroups.
Results
Sensitization of tumor cells to radiation by T-oligo
To determine if T-oligo can enhance the inhibition of
mammary tumor cell growth due to radiation, tumor
cells from MMT mice were cultured with T-oligo at
concentrations ranging from 0 to 40 μMf o r2 4h o u r s
and then irradiated. Tumor cells cultured in DMEM
medium alone or DMEM containing the same concen-
tration of a control oligo were used as controls. The
cells were collected and counted at 0, 24, 48, 72 and 96
hours after exposure to 3 Gy IR. T-oligo alone inhibited
growth of tumor cells in a dose dependent manner, with
the most marked inhibition at 40 μMT - o l i g o( d a t an o t
shown). However, inhibition was significantly enhanced
after IR and significant inhibitory effects were observed
in tumor cells treated with 30 to 40 μM T-oligo and 3
Gy IR (Figure 1a). This group of tumor cells declined in
numbers while the control-oligo-treated tumor cells,
though exposed to the same dose of 3 Gy, continued to
replicate (Figure 1a). These results suggest enhanced
inhibition of mammary tumor cells treated with T-oligo
and 3 Gy radiation. The inhibition of growth after 40
μM T-oligo and 3 Gy IR was more pronounced than in
cells treated with control-oligo or diluent alone (P =
0.019) and 6, 9 or 12 Gy (Figure 1b).
The clonogenic cell survival assay is the gold standard
to measure the radiosensitivity of cells. To determine if
T-oligo can sensitize mammary tumor cells to radiation,
tumor cells pretreated for 24 hours with T-oligo, con-
trol-oligo or medium alone were irradiated with indi-
cated doses of radiation and then the surviving fraction
of cells (those capable of colony formation) was deter-
mined. As shown in Figure 1c, the survival curve of
tumor cells treated with T-oligo and IR shifted to the
left considerably compared with those treated with con-
trol-oligo or medium and 3 Gy, suggesting significant
radiosensitization of tumor cells by T-oligo (Figure 1c).
T h em e a nl e t h a ld o s e( D 0) for tumor cells treated with
radiation plus T-oligo, control-oligo or medium alone
was 1.46, 2.98 and 3.36 Gy, respectively (Figure 1c). The
survival fraction at 2 Gy (SF2 = 0.31) for tumor cells
treated with T-oligo and radiation are comparable to
those of cell lines considered to be radiosensitive [23].
Thus pretreatment with T-oligo increases the sensitivity
of tumor cells to radiation and the combined treatment
with T-oligo and radiation can lead to cell growth arrest
and/or death as demonstrated by the clonogenic assay.
Mechanism of T-oligo-induced hypersensitivity to
radiation
To investigate potential mechanisms behind radiosensi-
tization of tumor cells by T-oligo, we next examined the
levels of nuclear-foci containing phosphorylated H2AX
(H2AX), a modification that occurs at sites of DNA
breaks [24]. Figure 2a shows representative immuno-
fluorescent images of gH2AX foci in treated mammary
tumor cells. Increased numbers of gH2AX foci per cell
were observed in tumor cells treated with T-oligo and 3
Gy IR at every time point after radiation compared with
those in tumor cells treated with control-oligo or med-
ium alone and 3 Gy (Figure 2a, b). The difference in
gH2AX-focus number between tumor cells treated with
T-oligo and IR and control groups at 1, 3, 6 and 24
hours is statistically significant (Figure 2b). These results
suggest that T-oligo enhances radiation-induced DNA
damage signal and/or delays DNA repair, although T-
oligo alone is known to transiently induce gH2AX foci
at telomeres in the apparent absence of double strand
DNA breaks or other damage [25]. We next compared
DNA fragmentation in tumor cells treated with T-oligo
and 3Gy IR using the comet assay [26]. Very modest
DNA fragmentation indicated by percentage of DNA in
tails, was observed in tumor cells treated with T-oligo
or 3 Gy IR alone, while cells treated with control-oligo
or medium alone showed no fragmentation (Figure 2c,
d). However, a significantly greater amount of fragmen-
ted DNA was detected three hours after 3 Gy IR
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Thus, combined treatment with T-oligo and radiation
results in enhanced response to DNA damage and/or
impaired DNA repair, leading to growth arrest and cell
death.
Increased induction of senescence and apoptosis in
tumor cells pretreated with T-oligo
As the above studies show that cells pretreated with T-
oligo are more sensitive to IR, we next determined
whether the treated cells undergo senescence or apopto-
sis. Tumor cells isolated from MMT mice were pre-
treated with T-oligo or control-oligo followed by
radiation and then examined 24 hours later for the
induction of senescence or apoptosis using senescence-
associated b-galactosidase (S.A. b-gal) and TUNEL
staining, respectively. Increased numbers of large (flat-
tened) cells positive for S.A. b-gal, two markers of
senescent cells, were observed after T-oligo treatment
compared with control-oligo treatment or medium
alone. However, b-gal-positive cells increased signifi-
cantly in tumor cells treated with T-oligo and 3 Gy
compared with control-oligo or no treatment and 3 Gy
(58.3 ± 6.3% vs 34.2 ± 7.5% or 26.1 ± 6.2%, Figure 3a,
b). A more profound effect of combined T-oligo and IR
was detected using the TUNEL assay. The apoptotic
rate increased significantly to 20.8 ± 8.5% (P = 0.036),
two to four times the control rates, in tumor cells trea-
ted with T-oligo and 3 Gy (Figure 3c, d). These results
indicate that senescence and apoptosis may be impor-
tant pathways to inhibit proliferation of murine mam-
mary tumor cells treated with T-oligo and IR. Both
responses may also contribute to the observed decrease
in clonogenic ability. Given that rates of senescence and
apoptosis have been previously observed to increase
steadily in T-oligo-treated malignant cells over two to
four days, depending on cell type [5-8], these determina-
tions made only 24 hours after irradiation, preceded by
an overnight T-oligo incubation, may underestimate the
eventual impact of the treatment.
Decreased tumorigenesis in mammary tumor cells treated
with T-oligo and irradiation
To determine whether tumor cells can still form
tumors in vivo after treatment with T-oligo and radia-
tion, mammary tumor cells were preincubated with T-
oligo or control-oligo for 24 hours followed by expo-
sure to 0 Gy (mock) or 3 Gy. The other control groups
were tumor cells supplemented with medium (diluent)
alone or exposed to 3 Gy of radiation alone. The
tumor cells (1 × 10
6) were then injected subcuta-
neously into the flanks of syngeneic wild-type mice. As
Figure 1 Inhibition of mammary tumor cell growth by T-oligo and ionizing radiation. (a) Mammary tumor cells isolated from MMT mice
were cultured with T-oligo at the concentration of 10, 20, 30 and 40 μM for 24 hours. Tumor cells cultured with control-oligo at the
concentration of 40 μM or medium alone were used as control. On Day 2, the cells were exposed to 3 Gy IR. The cells were then collected at
indicated time after radiation and counted in triplicates. (b) MMT tumor cells were cultured with T-oligo or control-oligo at a concentration of
40 μM for 24 hours and then irradiated with indicated dose of IR or mock irradiated (0 Gy). Seventy-two hours after IR, the cells were counted
using a particle counter in triplicates. Statistical significance from three independent experiments was determined by one-way ANOVA. (c)
Surviving fraction. The tumor cells were cultured in 10 cm tissue culture plates and pretreated with T-oligo or control-oligo at a concentration of
40 μM for 24 hours, and then irradiated with indicated doses. After two-weeks culture, the tumor colonies were fixed and stained with 0.5%
crystal violet. The colonies were counted with a cut-off of 50 viable cells. Surviving fractions were calculated by the number of colonies divided
as the number of seeded cells × plating efficiency.
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cells pretreated with T-oligo alone developed tumors,
but tumor size was reduced when compared with
untreated and control-oligo-treated tumor cells on Day
30 (Figure 4a, P = 0.02). However, the tumor forming
ability of mammary tumor cells treated with combined
T-oligo and 3 Gy irradiation was almost eradicated.
Only one out of four mice developed a tumor and this
small tumor did not appear until after Day 25 (Figure
4b). The difference in volume for tumor arising from
cell populations treated with T-oligo vs control-oligo
or medium alone, followed by 3 Gy, was highly statisti-
cally significant (P = 0.001, Figure 4b). Next, to deter-
mine if T-oligo and radiation induce apoptosis in
tumor cells injected into mice, sections of tumors from
all groups were stained for apoptosis using the TUNEL
assay. In tumors arising from cells pretreated once
with T-oligo alone we observed far more apoptosis
even after 30 days compared with control-oligo or
medium alone (Figure 4c). Few or no TUNEL-positive
cells were observed in tumors arising from control-
oligo or medium treated cells, and 3 Gy irradiation did
not increase the apoptosis to a statistically significant
degree (Figure 4c, d). In tumors arising from cells trea-
ted with combined T-oligo and radiation, the numbers
of apoptotic cells increased significantly (P = 0.043)
even after 30 days. At this time, an approximately
three- to six-fold increase in apoptosis was observed in
tumor cells treated with T-oligo vs control-oligo or
medium alone prior to subcutaneous injection (Figure
4d). The one small tumor found in one mouse inocu-
lated with tumor cells treated with T-oligo followed by
3 Gy IR contained many apoptotic cells (Figure 4c,
bottom right panel). These experiments provide further
evidence that pretreatment with T-oligo can enhance
the apoptotic killing of tumor cells by radiation, even
by radiation doses that alone have only a modest
effect.
Figure 2 Assessment of DNA damage responses and DNA repair. (a, b) Immunofluorescence staining for gH2AX. Tumor cells isolated from
MMT mice were cultured with T-oligo or control-oligo at a concentration of 40 μM for 24 hours in chamber slides. After 3 Gy IR, cells were
stained with FITC-anti-gH2AX mAb at indicated time. The number of gH2AX foci per cell was counted and calculated from at least 70 cells in
each group after subtraction of gH2AX foci from the un-irradiated tumor cells and presented as means ± SD from repeated experiments.
Statistical significance was determined by one-way ANOVA. (c, d) Comet assay. Tumor cells treated with T-oligo or control-oligo (40 μM) or
medium with or without 3 Gy IR 24 hours later were assessed for DNA repair at three hours after IR using Trevigen’s CometAssay® kit. Comet
images were selected randomly from the microscope field of view using a defined sequence of searching to ensure the same image was only
scored once. Statistical significance was determined by one-way ANOVA.
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spontaneous mammary carcinomas in vivo
When evaluating the efficacy of a therapy for breast can-
cer, it is desirable to use a tumor model that resembles
breast cancer in humans as closely as possible. We
[16,27] and others [15,28] have demonstrated that
PyMT-induced mammary tumors share many features in
common with human breast cancer. Therefore, MMT
mice were used to evaluate the combined effect of T-
oligo and radiotherapy in the in vivo setting. Our pre-
vious studies showed that mammary tumors in MMT
mice at Days 70 to 80 are in the early invasive stage [16].
MMT mice (n = 9) aged 70 to 72 days received intraduc-
tal injections of T-oligo at a dose of 210 μgi n5 0μLP B S
every other day in a right chest mammary gland. A left
chest mammary gland was injected with the same dose of
control-oligo as a same animal control. After seven to
eight injections, the mice were irradiated with a single
dose of 3 Gy focused on the chest area. The control
groups consisted of three littermates each that received
no treatment, treated with T-oligo and control-oligo
without radiation or treated with 3 Gy IR alone. Ten days
after irradiation, the mice were sacrificed and the treated
and control mammary glands harvested, processed for
w h o l em o u n t ,a n dd i g i t i z e d .T h et u m o ri nt h ed i g i t a l
image was traced and analyzed by SPOT advanced soft-
ware. As shown in Figure 5a, b, mammary tumors in the
mice without treatment or treated with 3 Gy alone
reached the size of 58 ± 6.11 mm
2 and 48 ± 14.18 mm
2,
respectively, statistically comparable. Treatment with T-
oligo or control-oligo witho u ti r r a d i a t i o nr e s u l t e di n
tumor sizes of 20.3 ± 8.96 mm
2 and 48.6 ± 30.1 mm
2,
respectively. However, the average tumor size in the right
mammary gland treated with T-oligo and 3Gy IR was
reduced to 8.67 ± 3.61 mm
2, compared with the average
tumor size of 27.67 ± 8.69 mm
2 in the left mammary
gland treated with control-oligo and 3 Gy IR. This reduc-
tion in tumor size was highly statistically significant (P <
0.001). The reduction in tumor size is more than the
combined reduction by the treatment of T-oligo or radia-
tion alone when compared with those in the no treat-
ment group. Consistent with the observed reduction in
tumor size, there was a striking increase in TUNEL posi-
tive cells 10 days post-irradiation in T-oligo treated
tumors (Figure 5c, d). Taken together, these results indi-
cate that an additive or synergistic effect of T-oligo and
radiation therapy can be achieved in a murine model that
is closely related to breast cancer in humans.
Figure 3 Increased senescence and apoptosis in tumor cells treated by T-oligo and IR. Mammary tumor cells isolated from MMT mice
were treated with 40 μM T-oligo, Control-oligo or medium (diluent) alone for 24 hours and then irradiated. Cells cultured in medium alone
were used as control. The tumor cells were collected 24 hours after 3 Gy IR and assayed for senescence and apoptosis. (a, b) b-gal staining. (a)
The cells stained blue are b-gal positive cells (magnification 60×). (b) Percentage of b-gal positive cells in T-oligo or control-oligo-treated dishes
with or without IR is presented in a bar graph. (c, d) TUNEL staining. (c) The cells stained in brown color are apoptotic cells (magnification 60×).
(d) Percentage of apoptotic positive cells in T-oligo or control-oligo-treated tumor cells with or without IR is presented in a bar graph. Statistical
significance from repeated experiments was determined by X
2-test.
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Ionizing radiation induces both single- and double-strand
DNA breaks (DSB) in cells that then trigger DNA damage
responses characterized by the recruitment of DNA-repair
proteins to gH2AX foci at sites of DNA damage and the
activation of checkpoint proteins that arrest cell cycle pro-
gression [29]. Cell cycle arrest is a protective cellular
response understood to block cell cycle progression and to
permit DNA damage repair [29]. An increase in DNA
damage, reduced ability to repair DNA damage, and/or
prolonged checkpoint activation can cause apoptosis [30]
or cause cells to undergo permanent cell cycle arrest
(senescence) [31]. We show here that pretreatment with
T-oligo sensitizes mammary tumor cells to radiation, pro-
moting growth inhibition and death of tumor cells in vitro
and in an in vivo mouse model.
The mechanism by which T-oligo sensitize tumor cells
remains to be fully elucidated. Although T-oligos do not
act as telomerase inhibitors [12] or cause digestion of
the 3’ telomere overhang [5,25,32], T-oligos have been
shown to rapidly concentrate in nuclei when added to
cultured cells and the subsequent responses require
WRN [25], the protein mutated in the progeroid cancer-
prone Werner syndrome. T-oligo/WRN interaction
results in formation of DNA gH2AX damage-like foci at
the telomeres [25] with activation of ATM [8,32] and its
many downstream effector proteins, leading to apoptosis
and senescence [5,7,8,32]. In the present study, pretreat-
ment with T-oligo enhances the formation of gH2AX
foci (Figure 2) that customarily form at sites of DNA
damage but after T-oligo treatment form at telomeres in
the absence of detectable DNA damage [25]. Activating
Figure 4 Loss of tumor forming ability in mammary tumor cells treated with T-oligo and radiation. (a, b) Mammary tumor cells were
cultured in medium containing 40 μM T-oligo, control-oligo, or no additive. After 24 hours of culture, the tumor cells from each group were
collected, counted, placed in the 50 ml polypropylene tube on ice and then irradiated with 0 or 3 Gy, respectively. Then 1 × 10
6 tumor cells
from each group with or without irradiation were injected subcutaneously into right or left flanks of syngeneic wild-type mice (n = 4/group).
Mice (n = 4/group) injected with tumor cells cultured with medium alone and/or that received radiation alone were used as controls. Tumor
size was measured with calipers every other day for 30 days and tumor volume was calculated using the formula: tumor volume = (longer
diameter × shorter diameter
2)/2. The average tumor volume was calculated and presented at indicated days after tumor inoculation. The tumor
incidence was indicated as the numbers of tumor-bearing mice/total numbers of mice in each group in the graph. Statistical significance was
determined by one-way ANOVA. (c) Sections of tumors from mice inoculated with tumor cells treated in vitro with T-oligo or control-oligo
followed by 0 or 3 Gy radiation were stained for apoptosis via TUNEL assay and then photographed at 40× magnification. (d) The cells stained
brown are apoptotic. The apoptotic cells were counted in three to five randomly selected fields at 40× magnification. The percentage of
apoptotic cells among all tumor cells is graphed and statistical significance was determined by X
2-test.
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ment, as demonstrated to occur over several days in
multiple cell types including breast carcinoma cells
[5-7,9], could render tumor cells more apt to undergo
apoptosis or senescence when exposed to IR. Alterna-
tively, tumor cell inactivation could be due to the
impairment of DNA repair by the pretreatment with T-
oligo as demonstrated by slower decay of gH2AX foci
and increased fragmentation of DNA in the comet assay
(Figure 2). Increased radiosensitivity has been found in
cells from patients with DDR or DNA-repair disorders
such as Ataxia Telangiectasia (defect in ATM), Nijme-
gen Breakage Syndrome (defect in NBS1), Fanconi ane-
mia, defective Artemis, DNA ligase I and DNA ligase IV
[33]. We favor a model of radiosensitization by T-oligos
that encompasses the known and hypothesized effects of
both IR and T-oligos: After 24 hours pretreatment, T-
oligo-treated cells have entered an S-phase arrest
[5-8,11] mediated by p95/Nbs1 [10], presumptively due
to G-quadruplex formation between single stranded
telomeric DNA and the G-rich T-oligos [12] with conse-
quent stalling of replication forks [34]. Without further
intervention, malignant cells then begin to undergo
apoptosis [5-8,11] or to enter senescence [8,35] or both,
as in the case of breast carcinoma cells in this study and
a previous one [8], presumably in response to the col-
lapse of their stalled replication forks. If such cells are
then irradiated, the introduction of even modest
Figure 5 Effect of T-oligo and radiation therapy on spontaneous mammary carcinomas in vivo. (a) Photos of whole-mounted mammary
glands. Panels show representative mammary gland/tumor harvested from mice injected with control-oligo (left side) and T-oligo (right side),
respectively. After seven to eight injections, the mammary glands (chest area) of oligo-treated mice (n = 9) and untreated mice (n = 3) were
irradiated with 3 Gy after being anesthetized with intraperitoneal administration of ketamine (75 mg/kg) and xylazine (5 mg/kg). The remaining
oligo-treated and untreated mice (n = 3) that received no IR were used as control. The mice were sacrificed on Day 10 after irradiation and
mammary glands were harvested, processed for whole mount and photographed. The dark nodules circled by red line are the mammary
tumors. (b) Comparison of tumor size from the treated and control mice. The whole mount was digitized and the tumors were traced and
measured using SPOT advanced software. Statistical analysis was performed using t-test. Untreated right (R) and left (L) chest mammary glands
in mice receiving either 0 Gy or 3 Gy, were harvested and tumor size is presented separately to show the minimal and insignificant site variation.
(c) TUNEL staining. The mammary tissues in panel A were fixed, sectioned and stained for apoptosis (60×). (d) The apoptotic (brown) cells were
counted by two investigators and the percentage of apoptotic cells among each group (n = 3/group) was calculated and presented in bar
graph. Statistical significance was determined by X
2-test.
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enhances the replication stress and the processes of
apoptosis and senescence.
Regardless of its mechanism of action, T-oligo pre-
treatment increased tumor cell sensitivity to radiation as
demonstrated by the clonogenic assay (Figure 1). The
present data suggest that combining T-oligos with low
dose IR may permit safer and more effective radiother-
apy of breast cancer and potentially other malignancies.
T-oligo adjuvant therapy would thus be very beneficial
to patients otherwise at risk of short-term and long-
term adverse effects of IR, including radiation dermati-
tis, fibrosis, compromised wound healing, and secondary
malignancies [36]. T-oligos when applied alone are with-
out detectable adverse effects on normal tissues after
either local or systemic administration in multiple
mouse models [6,8,9,11,12] including the MMT mice. In
accordance with this, we did not observe adverse effects
in mice exposed to this agent and 3Gy IR including
lethargy, anorexia, inactivity, ruffled fur coat or diarrhea.
The murine mammary tumor induced by PyMT
shares many features with poor-prognosis human breast
cancer such as a high frequency of distant metastases,
persistent expression of biomarkers, ErbB2/Neu and
cyclin D1, and loss of estrogen and progesterone recep-
tor expression [28]. In addition, the tumors develop in
multiple stages amid a competent immune system, a
trait also shared by human breast cancer [22]. These
advantages would appear to outweigh the greater indivi-
dual variation in mammary tumor development in
MMT mice versus mice bearing xenografts of estab-
lished breast cancer cell lines. MMT mice thus provide
a reliable model for the study of tumorigenesis in breast
cancer as well as a useful tool for the evaluation of
treatment modalities.
Conclusions
In this study, we demonstrated that pretreatment with
T-oligo sensitizes mammary tumor cells to radiation in
vitro and in vivo tumor models. The inhibition of tumor
cells by pretreatment with T-oligo was associated with
increased induction of senescence and apoptosis of irra-
diated tumor cells and reduced clonogenesis, presum-
ably due to the observed increased formation and/or
delayed resolution of DNA damage response foci.
Further studies of combined T-oligo/IR therapy are
warranted.
Abbreviations
b-gal: b-galactosidase; gH2AX: phosphorylated histone H2AX; DDR: DNA
damage response; DSB: double-strand DNA breaks; IR: Ionizing radiation;
PyMT: polyomavirus middle T oncogene; Tg: transgenic; T-oligos:
oligonucleotides homologous to the telomere G-rich sequence TTAGGG;
TUNEL assay: terminal deoxynucleotidyl transferase dUTP Nick End Labeling
assay.
Acknowledgements
This work is supported by a grant from Susan G. Komen for the Cure
(BCTR0503792) and institutional funding.
Author details
1Department of Medicine, Boston University School of Medicine, 72 E
Concord St, Boston, MA 02118, USA.
2Department of Radiation Oncology,
Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney St, Boston,
MA 02115, USA.
3Department of Dermatology, Boston University School of
Medicine, 72 E Concord St, Boston, MA 02118, USA.
4Molecular and Cellular
Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical
School, 330 Brookline Avenue, Boston, MA 02215, USA.
Authors’ contributions
DW participated in the design of the study, carried out clonogenic cell
survival and comet assays, immunofluorescence staining, T-oligo treatment
and radiation experiments, and performed the statistical analysis. MCC
participated in the design of the study, carried out cell counting, b-gal and
TUNEL staining, T-oligo treatment and radiation experiments. BS participated
in the design of the study and helped draft the manuscript. BDP, MSE and
BAG provided expert views in the radiation experiment and helped revise
the manuscript. SKC participated in the drafting of the manuscript. JG
conceived of the study, designed, coordinated and participated in the
experiments, and drafted the manuscript. All authors read and approved the
manuscript.
Competing interests
Two co-authors, Mark Eller and Barbara Gilchrest, have equity in the for-
profit start-up company SemaCo and a patent related to the content of the
manuscript. Barbara Gilchrest is Semaco’s Chief Scientific Officer.
Received: 13 March 2010 Revised: 7 August 2010
Accepted: 16 September 2010 Published: 16 September 2010
References
1. McClintock B: The stability of broken ends of chromosomes in Zea mays.
Genetics 1941, 26:234-282.
2. Karlseder J, Smogorzewska A, de Lange T: Senescence induced by altered
telomere state, not telomere loss. Science 2002, 295:2446-2449.
3. Karlseder J, Broccoli D, Dai Y, Hardy S, de Lange T: p53- and ATM-
dependent apoptosis induced by telomeres lacking TRF2. Science 1999,
283:1321-1325.
4. de Lange T: Protection of mammalian telomeres. Oncogene 2002,
21:532-540.
5. Eller MS, Puri N, Hadshiew IM, Venna SS, Gilchrest BA: Induction of
apoptosis by telomere 3’ overhang-specific DNA. Exp Cell Res 2002,
276:185-193.
6. Puri N, Eller MS, Byers HR, Dykstra S, Kubera J, Gilchrest BA: Telomere-based
DNA damage responses: a new approach to melanoma. Faseb J 2004,
18:1373-1381.
7. Ohashi N, Yaar M, Eller MS, Truzzi F, Gilchrest BA: Features that determine
telomere homolog oligonucleotide-induced therapeutic DNA damage-
like responses in cancer cells. J Cell Physiol 2007, 210:582-595.
8. Yaar M, Eller MS, Panova I, Kubera J, Wee LH, Cowan KH, Gilchrest BA:
Telomeric DNA induces apoptosis and senescence of human breast
carcinoma cells. Breast Cancer Res 2007, 9:R13.
9. Aoki H, Iwado E, Eller MS, Kondo Y, Fujiwara K, Li GZ, Hess KR, Siwak DR,
Sawaya R, Mills GB, Gilchrest BA, Kondo S: Telomere 3’ overhang-specific
DNA oligonucleotides induce autophagy in malignant glioma cells. Faseb
J 2007, 21:2918-2930.
10. Eller MS, Li GZ, Firoozabadi R, Puri N, Gilchrest BA: Induction of a p95/
Nbs1-mediated S phase checkpoint by telomere 3’ overhang specific
DNA. Faseb J 2003, 17:152-162.
11. Longe HO, Romesser PB, Rankin AM, Faller DV, Eller MS, Gilchrest BA,
Denis GV: Telomere homolog oligonucleotides induce apoptosis in
malignant but not in normal lymphoid cells: mechanism and
therapeutic potential. Int J Cancer 2009, 124:473-482.
12. Gilchrest BA, Eller MS: Cancer therapeutics: smart and smarter. Drugs of
the Future 2009, 34:205-216.
13. Sobeck A, Stone S, Costanzo V, de Graaf B, Reuter T, de Winter J,
Wallisch M, Akkari Y, Olson S, Wang W, Joenje H, Christian JL, Lupardus PJ,
Weng et al. Breast Cancer Research 2010, 12:R71
http://breast-cancer-research.com/content/12/5/R71
Page 10 of 11Cimprich KA, Gautier J, Hoatlin ME: Fanconi anemia proteins are required
to prevent accumulation of replication-associated DNA double-strand
breaks. Mol Cell Biol 2006, 26:425-437.
14. Wang LC, Stone S, Hoatlin ME, Gautier J: Fanconi anemia proteins stabilize
replication forks. DNA Repair (Amst) 2008, 7:1973-1981.
15. Rowse GJ, Tempero RM, VanLith ML, Hollingsworth MA, Gendler SJ:
Tolerance and immunity to MUC1 in a human MUC1 transgenic murine
model. Cancer Res 1998, 58:315-321.
16. Xia J, Tanaka Y, Koido S, Liu C, Mukherjee P, Gendler SJ, Gong J: Prevention
of spontaneous breast carcinoma by prophylactic vaccination with
dendritic/tumor fusion cells. J Immunol 2003, 170:1980-1986.
17. Amorino GP, Mikkelsen RB, Valerie K, Schmidt-Ullrich RK: Dominant-
negative cAMP-responsive element-binding protein inhibits proliferating
cell nuclear antigen and DNA repair, leading to increased cellular
radiosensitivity. J Biol Chem 2003, 278:29394-29399.
18. Lee JH, Kang Y, Khare V, Jin ZY, Kang MY, Yoon Y, Hyun JW, Chung MH,
Cho SI, Jun JY, Chang IY, You HJ: The p53-inducible gene 3 (PIG3)
contributes to early cellular response to DNA damage. Oncogene 2010,
29:1431-1450.
19. Itahana K, Campisi J, Dimri GP: Methods to detect biomarkers of cellular
senescence: the senescence-associated beta-galactosidase assay.
Methods Mol Biol 2007, 371:21-31.
20. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE,
Linskens M, Rubelj I, Pereira-Smith O, et al: A biomarker that identifies
senescent human cells in culture and in aging skin in vivo. Proc Natl
Acad Sci USA 1995, 92:9363-9367.
21. Chen D, Koido S, Li Y, Gendler S, Gong J: T cell suppression as a
mechanism for tolerance to MUC1 antigen in MUC1 transgenic mice.
Breast Cancer Res Treat 2000, 60:107-115.
22. Jaskelioff M, Song W, Xia J, Liu C, Kramer J, Koido S, Gendler SJ,
Calderwood SK, Gong J: Telomerase deficiency and telomere dysfunction
inhibit mammary tumors induced by polyomavirus middle T oncogene.
Oncogene 2009, 28:4225-4236.
23. Malaise EP, Fertil B, Chavaudra N, Guichard M: Distribution of radiation
sensitivities for human tumor cells of specific histological types:
comparison of in vitro to in vivo data. Int J Radiat Oncol Biol Phys 1986,
12:617-624.
24. Kinner A, Wu W, Staudt C, Iliakis G: Gamma-H2AX in recognition and
signaling of DNA double-strand breaks in the context of chromatin.
Nucleic Acids Res 2008, 36:5678-5694.
25. Eller MS, Liao X, Liu S, Hanna K, Backvall H, Opresko PL, Bohr VA,
Gilchrest BA: A role for WRN in telomere-based DNA damage responses.
Proc Natl Acad Sci USA 2006, 103:15073-15078.
26. Eastham AM, Marples B, Kiltie AE, Orton CJ, West CM: Fibroblast
radiosensitivity measured using the comet DNA-damage assay
correlates with clonogenic survival parameters. Br J Cancer 1999,
79:1366-1371.
27. Jaskelioff M, Song W, Xia J, Liu C, Kramer J, Koido S, Gendler SJ,
Calderwood SK, Gong J: Telomerase deficiency and telomere dysfunction
inhibit mammary tumors induced by polyomavirus middle T oncogene.
Oncogene 2009, 28:4225-4236.
28. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, Pollard JW:
Progression to malignancy in the polyoma middle T oncoprotein mouse
breast cancer model provides a reliable model for human diseases. Am J
Pathol 2003, 163:2113-2126.
29. Zhou BB, Elledge SJ: The DNA damage response: putting checkpoints in
perspective. Nature 2000, 408:433-439.
30. Rich T, Allen RL, Wyllie AH: Defying death after DNA damage. Nature 2000,
407:777-783.
31. Schmitt CA: Senescence, apoptosis and therapy–cutting the lifelines of
cancer. Nat Rev Cancer 2003, 3:286-295.
32. Li GZ, Eller MS, Firoozabadi R, Gilchrest BA: Evidence that exposure of the
telomere 3’ overhang sequence induces senescence. Proc Natl Acad Sci
USA 2003, 100:527-531.
33. Castella M, Puerto S, Creus A, Marcos R, Surralles J: Telomere length
modulates human radiation sensitivity in vitro. Toxicol Lett 2007,
172:29-36.
34. Woodford KJ, Howell RM, Usdin K: A novel K(+)-dependent DNA synthesis
arrest site in a commonly occurring sequence motif in eukaryotes. J Biol
Chem 1994, 269:27029-27035.
35. Li GZ, Eller MS, Hanna K, Gilchrest BA: Signaling pathway requirements for
induction of senescence by telomere homolog oligonucleotides. Exp Cell
Res 2004, 301:189-200.
36. Hall EJ, Giaccia AJ: Radiobiology for the Radiologist Philadelphia: Lippincott
Wilkins & Williams 2006.
doi:10.1186/bcr2639
Cite this article as: Weng et al.: Radiosensitization of mammary
carcinoma cells by telomere homolog oligonucleotide pretreatment.
Breast Cancer Research 2010 12:R71.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Weng et al. Breast Cancer Research 2010, 12:R71
http://breast-cancer-research.com/content/12/5/R71
Page 11 of 11